Late-stage biopharmaceutical company Pharvaris N.V. (PHVS) is heading into the stretch where science meets the scoreboard. The company expects topline results in the fourth quarter of 2025 from RAPIDe-3, its pivotal Phase 3 trial evaluating deucrictibant for the on-demand treatment of HAE attacks.
The study reached target enrollment in March and continues to assess hereditary angioedema (HAE) attacks in enrolled participants. RAPIDe-3 is testing the immediate-release capsule formulation of deucrictibant at a 20 mg dose, which is the intended commercial dosage for acute treatment in adults and adolescents aged 12 and older.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.